Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress ...

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...